Oxidative phenotype and metabolic ratio (MR) of debrisoquine (DBQ) have been determined in 87 patients with Parkinson's disease and in 556 healthy control subjects. Three patients (3-45%) and 34 control subjects (6-12%), having an MR > 12-6, were classified as poor metabolisers (PM) of DBQ (ns). 
subjects. Three patients (3-45%) and 34 control subjects (6-12%), having an MR > 12-6, were classified as poor metabolisers (PM) of DBQ (ns). The The cause of Parkinson's disease is unknown. However, genetic predisposition, ageing, and neurotoxicity by chemicals, may all play a role.'5 Barbeau et al'6 determined the oxidative polymorphism of DBQ in a group of Parkinsonian patients and stated that "poor metabolisers among PD patients tended to have an earlier age at onset of the disease". Afterwards, the same group'7 attributed much of that lower oxidative rate to enzymatic blocking caused by the concurrent administration of the antihistamine drugs diphenhydramine or orphenadrine, but concluded that "the observation that non-(poor) metabolisers of debrisoquine tend to have an earlier age of onset and an early severe course of PD still holds true". Comella et al and Tanner et al 18 19 detected a non-significant excess of slow metabolisers of DBQ in their patients aged under 40 years at clinical onset.
In this study we have aimed to elucidate the possible relationship between Parkinson's disease and oxidative polymorphism of DBQ, taking particular care to eliminate bias produced by the concomitant use of drugs capable of interfering with its enzymatic activity.
Debrisoquine (DBQ), an adrenergic-blocking drug, is oxidised in the liver to 4-hydroxydebrisoquine (4-OH DBQ) following a polymorphic reaction that depends on the isozyme dbl of the microsomal cytochrome P-450 system (P-450 II Dl In the subgroup A ("untreated"), age at onset of the disease and MR values were inversely and significantly related (r = -0-36, p < 0 02). The only PM patient in the subgroup A was a male whose age of disease onset was 24 years. In the other patient in subgroup A with young onset (<40 years) symptoms began at age 33. In contrast, no correlation with age was found when analysing either subgroup B ("treated") or the whole series.
Clinical stage ofthe disease was not related to MR values in either the whole series or in subgroups A and B considered separately.
Discussion
The distribution of the oxidative polymorphism of DBQ in our patients with Parkinson's disease did not differ from that found in the control group. Nevertheless, when analysing separately the distribution of MR of DBQ just in extensive metabolisers, we found a lower oxidative rate in EM patients than in EM controls.
Although mean age is lower in the control group than in patients, ageing does not reduce the oxidative rate of DBQ. 14 Subgroup A ("untreated") includes both genuinely untreated patients and patients on treatment only with levodopa and/or bromocriptine, which do not interfere with the metabolism of DBQ.10 The distribution of MR values in EM patients of subgroup A is not different from that noticed in EM subjects of the control group (fig). However, when comparing the distribution of MR values between EM subjects of the group of patients treated with drugs capable of interfering with dbl P-450 isozyme (subgroup B, "treated") and EM control subjects, significantly (p < 0-001) higher. MR values were detected in patients.
This reduction in the oxidative rate of DBQ in these "treated"-Parkinsonian patients with the EM phenotype is probably due to the inhibitory effect that some drugs exert on the cytochrome 
